12/12/2025 Arcus and Gilead have discontinued the Phase 3 STAR-221 trial of their TIGIT regimen in gastric and esophageal cancers Johnson & Johnson's AKEEGA received FDA approval for BRCA2-mutated CSPC Arcus and Gilead have discontinued the Phase 3 STAR-221 trial of their TIGIT regimen in gastric and esophageal cancers (Ref) The Phase 3 STAR-221 trial of Arcus Biosciences and Gilead's domvanalimab (anti-TIGIT) + zimberelimab (anti-PD-1) + chemotherapy vs nivolumab + chemother

14/08/2025 Halda's HLD-0915 received the Fast Track Designation from the US FDA for mCRPC (Ref) The US FDA granted the Fast Track designation to Halda Therapeutics' HLD-0915 (androgen receptor-targeting RIPTAC) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). A Phase 1/2 trial of HLD-0915 in mCRPC is ongoing to evaluate the safety, tolerability, PK, PD, and anti-tumor activity Christian Schade, President and CEO, Halda Therapeutics:

18/06/2025 The Phase 3 IDeate-Prostate01 trial of ifinatamab deruxtecan has been initiated in pretreated, metastatic CRPC patients (Ref) The first patient has been dosed in the Phase 3 IDeate-Prostate01/NCT06925737 trial evaluating Daiichi Sankyo and Merck & Co./MSD's ifinatamab deruxtecan (I-DXd; B7-H3 ADC) vs docetaxel in patients with metastatic castration-resistant prostate cancer (CRPC) with disease progression during or after treatment with an androgen receptor pathway